Potential organotoxicity liabilities in the same animal


This assay is a medium/high-throughput preclinical zebrafish embryo screen capable of identifying compounds with potential organotoxicity liabilities in the same animal.

The system offers a quick and economical tool for assessing potential toxicities in large libraries of molecules at a deep morphological and functional level early in drug development. It has the potential to reduce the number of compounds entering regulatory in vivo studies and to reduce costly late-stage attrition.

The core principle of ZeGlobalTox is to extract reproducible results on acute toxicity, teratogenicity, cardio-, neuro- and hepato-toxicity in the same animal from microscope images of zebrafish embryos exposed to novel compounds. The entire process from the treatment of the animals to image acquisition and analysis is automated, making the technology easy to adopt and integrate into existing testing strategies. In addition, includes a method to analyze vascular toxicity, by video recording blood vessels and software-driven analyze blood flow and vessel diameters.

The ZeGlobalTox platform uses zebrafish embryos younger than five days old and so are not protected animals requiring an ethical license. It combines fluorescent or bright-field images and specific analytical software to extract information about the functionality of the organs or tissues in response to compounds in a revolutionary way.


Download our ZeGlobalTox Paper

Supported by
Pivot Park HollandNoldus Technology Holland


Just tell us your biological/pharmacological question and we propose and run the best zebrafish-based scientific methodology and provide reliable results. Rare diseases, gene functions, biological pathways, drug-target interaction, drug accumulations and much more can be developed and studied in zebrafish.


Request information about ZeGlobalTox: